Mifepristone Drug-Drug Interaction Study With CYP3A Inhibitor

Completed · Phase 1

Conditions studied: Drug Interaction Potentiation, Healthy

In brief

This is a Phase 1, single-center, fixed-sequence, open label, drug-drug interaction study of the effect of multiple daily doses of oral itraconazole 200 mg, a strong inhibitor of CYP3A, given with mifepristone 900 mg QD, in healthy male subjects, where all drug administrations are given after a meal.

Key facts

Study ID
NCT03259542
Run by
Corcept Therapeutics
People needed
33
Starts
2017-08-09
Expected to finish
2017-12-11
Last updated by the study team
2018-02-22

Who can join

Age: 18 and older, up to 65. Sex: male. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.